The US District Court for the Northern District of California reaffirms the importance of market definition in antitrust merger analysis (Golden Gate Pharmacy / Pfizer)

On April 16, 2010, Judge Maxine M. Chesney of the U.S. District Court for the Northern District of California dismissed a complaint raising a private antitrust challenge to the merger of Pfizer, Inc. and Wyeth Pharmaceuticals, because she concluded that the complaint failed sufficiently to allege the existence of a cognizable relevant product market. See Golden Gate Pharmacy Servs., Inc. v. Pfizer, Inc., No. C-09-3854, 2010 WL 1541257 (N.D. Cal. Apr. 16, 2010). In dismissing the complaint, which plaintiffs already had amended twice, Judge Chesney applied established case law that emphasizes the importance of properly defining a relevant market when determining whether a merger violates the antitrust laws. Judge Chesney’s decision is noteworthy coming just four days before the

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Skadden, Arps, Slate, Meagher & Flom (Washington)
  • Skadden, Arps, Slate, Meagher & Flom (New York)

Citation

Gary A. MacDonald, Matthew P. Hendrickson, The US District Court for the Northern District of California reaffirms the importance of market definition in antitrust merger analysis (Golden Gate Pharmacy / Pfizer), 16 avril 2010, e-Competitions April 2010, Art. N° 45422

Visites 386

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues